This is something that the NBCC should address. We need a federal law to determine ownership of tissue samples.
Also the length of retention by the pathology labs vary from state to state.
As treatments become more targeted and drugs more expensive, it does not seem unreasonable that insurance companies will not pay for treatments unless certain markers in biopsied tissues indicate that the drug will be effective.
Regards
Joe
__________________
A Proud webmaster to the internet's most informed, educated, COMPASSIONATE and caring group of breast cancer survivors.
Illegitimi non carborundum
My Album
|